173 related articles for article (PubMed ID: 21345146)
21. The tumor suppressor CYLD regulates entry into mitosis.
Stegmeier F; Sowa ME; Nalepa G; Gygi SP; Harper JW; Elledge SJ
Proc Natl Acad Sci U S A; 2007 May; 104(21):8869-74. PubMed ID: 17495026
[TBL] [Abstract][Full Text] [Related]
22. Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive disease.
van Andel H; Kocemba KA; de Haan-Kramer A; Mellink CH; Piwowar M; Broijl A; van Duin M; Sonneveld P; Maurice MM; Kersten MJ; Spaargaren M; Pals ST
Oncogene; 2017 Apr; 36(15):2105-2115. PubMed ID: 27775078
[TBL] [Abstract][Full Text] [Related]
23. Linear ubiquitination in immunity.
Shimizu Y; Taraborrelli L; Walczak H
Immunol Rev; 2015 Jul; 266(1):190-207. PubMed ID: 26085216
[TBL] [Abstract][Full Text] [Related]
24. Tumor Suppressor Function of CYLD in Nonmelanoma Skin Cancer.
Masoumi KC; Shaw-Hallgren G; Massoumi R
J Skin Cancer; 2011; 2011():614097. PubMed ID: 22235375
[TBL] [Abstract][Full Text] [Related]
25. CYLD in ubiquitin signaling and tumor pathogenesis.
Ikeda F; Dikic I
Cell; 2006 May; 125(4):643-5. PubMed ID: 16713556
[TBL] [Abstract][Full Text] [Related]
26. Downregulation of cylindromatosis gene, CYLD, confers a growth advantage on malignant melanoma cells while negatively regulating their migration activity.
Ishikawa Y; Tsunoda K; Shibazaki M; Takahashi K; Akasaka T; Masuda T; Maesawa C
Int J Oncol; 2012 Jul; 41(1):53-60. PubMed ID: 22469839
[TBL] [Abstract][Full Text] [Related]
27. Tumour suppressor CYLD is a negative regulator of the mitotic kinase Aurora-B.
Sun L; Gao J; Huo L; Sun X; Shi X; Liu M; Li D; Zhang C; Zhou J
J Pathol; 2010 Aug; 221(4):425-32. PubMed ID: 20593489
[TBL] [Abstract][Full Text] [Related]
28. UV Irradiation Triggers Cylindromatosis Translocation, Modification, and Degradation in a Proteasome-Independent Manner.
Zhou P; Hao Z; Wang X; Gao J; Li D; Xie S; Zhang TC
DNA Cell Biol; 2016 Mar; 35(3):140-5. PubMed ID: 26717101
[TBL] [Abstract][Full Text] [Related]
29. Thymocyte-specific truncation of the deubiquitinating domain of CYLD impairs positive selection in a NF-kappaB essential modulator-dependent manner.
Tsagaratou A; Trompouki E; Grammenoudi S; Kontoyiannis DL; Mosialos G
J Immunol; 2010 Aug; 185(4):2032-43. PubMed ID: 20644164
[TBL] [Abstract][Full Text] [Related]
30. The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappaB activation by tumor necrosis factor.
Regamey A; Hohl D; Liu JW; Roger T; Kogerman P; Toftgard R; Huber M
J Exp Med; 2003 Dec; 198(12):1959-64. PubMed ID: 14676304
[TBL] [Abstract][Full Text] [Related]
31. Catalytic domain mutation in CYLD inactivates its enzyme function by structural perturbation and induces cell migration and proliferation.
Johari T; Maiti TK
Biochim Biophys Acta Gen Subj; 2018 Sep; 1862(9):2081-2089. PubMed ID: 29807073
[TBL] [Abstract][Full Text] [Related]
32. CYLD: a DUB with many talents.
Simonson SJS; Wu ZH; Miyamoto S
Dev Cell; 2007 Nov; 13(5):601-603. PubMed ID: 17981127
[TBL] [Abstract][Full Text] [Related]
33. Formation and removal of poly-ubiquitin chains in the regulation of tumor necrosis factor-induced gene activation and cell death.
Kupka S; Reichert M; Draber P; Walczak H
FEBS J; 2016 Jul; 283(14):2626-39. PubMed ID: 26749412
[TBL] [Abstract][Full Text] [Related]
34. Linear ubiquitination in NF-κB signaling and inflammation: What we do understand and what we do not.
Verhelst K; Verstrepen L; Carpentier I; Beyaert R
Biochem Pharmacol; 2011 Nov; 82(9):1057-65. PubMed ID: 21787758
[TBL] [Abstract][Full Text] [Related]
35. An inactivating CYLD mutation promotes skin tumor progression by conferring enhanced proliferative, survival and angiogenic properties to epidermal cancer cells.
Alameda JP; Moreno-Maldonado R; Navarro M; Bravo A; Ramírez A; Page A; Jorcano JL; Fernández-Aceñero MJ; Casanova ML
Oncogene; 2010 Dec; 29(50):6522-32. PubMed ID: 20838385
[TBL] [Abstract][Full Text] [Related]
36. GLI1-dependent transcriptional repression of CYLD in basal cell carcinoma.
Kuphal S; Shaw-Hallgren G; Eberl M; Karrer S; Aberger F; Bosserhoff AK; Massoumi R
Oncogene; 2011 Nov; 30(44):4523-30. PubMed ID: 21577203
[TBL] [Abstract][Full Text] [Related]
37. Tumor suppressor CYLD: negative regulation of NF-kappaB signaling and more.
Courtois G
Cell Mol Life Sci; 2008 Apr; 65(7-8):1123-32. PubMed ID: 18193168
[TBL] [Abstract][Full Text] [Related]
38. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
39. Down-regulation of the Tumor Suppressor CYLD Enhances the Transformed Phenotype of Human Breast Cancer Cells.
Orfanidou T; Xanthopoulos K; Dafou D; Pseftogas A; Hadweh P; Psyllaki C; Hatzivassiliou E; Mosialos G
Anticancer Res; 2017 Jul; 37(7):3493-3503. PubMed ID: 28668838
[TBL] [Abstract][Full Text] [Related]
40. CYLD-mediated signaling and diseases.
Mathis BJ; Lai Y; Qu C; Janicki JS; Cui T
Curr Drug Targets; 2015; 16(4):284-94. PubMed ID: 25342597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
